These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10205289)

  • 1. Tumour markers - new aspects of an old discussion?
    Fleischhacker M; Beinert T
    Eur J Med Res; 1999 Apr; 4(4):144-8. PubMed ID: 10205289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of molecular genetic studies in the diagnosis of solid tumors].
    Belokhvostov AS; Novik AA
    Vopr Onkol; 1999; 45(6):599-606. PubMed ID: 10703505
    [No Abstract]   [Full Text] [Related]  

  • 3. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating DNA in plasma or serum.
    Anker P; Stroun M
    Medicina (B Aires); 2000; 60(5 Pt 2):699-702. PubMed ID: 11188885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of molecular screening.
    Ahrendt SA; Sidransky D
    Surg Oncol Clin N Am; 1999 Oct; 8(4):641-56, vi. PubMed ID: 10452932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple detection of genetic alterations in tumors and stool.
    Rengucci C; Maiolo P; Saragoni L; Zoli W; Amadori D; Calistri D
    Clin Cancer Res; 2001 Mar; 7(3):590-3. PubMed ID: 11297253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring.
    Wong IH; Lo YM; Johnson PJ
    Ann N Y Acad Sci; 2001 Sep; 945():36-50. PubMed ID: 11708493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level microsatellite instability is not involved in gallbladder carcinogenesis.
    Saetta AA; Gigelou F; Papanastasiou PI; Koilakou SV; Kalekou-Greca H; Miliaras D; Michalopoulos NV; Patsouris E
    Exp Mol Pathol; 2006 Feb; 80(1):67-71. PubMed ID: 15963980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform.
    Lilleberg SL; Durocher J; Sanders C; Walters K; Culver K
    Ann N Y Acad Sci; 2004 Jun; 1022():250-6. PubMed ID: 15251969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical importance of serum anti-p53 antibodies as tumor markers].
    Sakai H; Okamoto E
    Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions.
    van Houten VM; Tabor MP; van den Brekel MW; Denkers F; Wishaupt RG; Kummer JA; Snow GB; Brakenhoff RH
    Clin Cancer Res; 2000 Oct; 6(10):3803-16. PubMed ID: 11051222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The molecular diagnosis of cancer].
    Barrera Saldaña H; Martínez Garza S; Ortiz López R
    Rev Invest Clin; 2003; 55(2):128-37. PubMed ID: 12827915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different genetic features associated with colon and rectal carcinogenesis.
    Frattini M; Balestra D; Suardi S; Oggionni M; Alberici P; Radice P; Costa A; Daidone MG; Leo E; Pilotti S; Bertario L; Pierotti MA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4015-21. PubMed ID: 15217933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer.
    Saetta AA
    J Surg Oncol; 2006 Jun; 93(8):644-9. PubMed ID: 16724348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive molecular markers in colorectal carcinoma.
    Bendardaf R; Lamlum H; Pyrhönen S
    Anticancer Res; 2004; 24(4):2519-30. PubMed ID: 15330208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor markers--serologic parameters for monitoring and therapeutic control of cancer patients].
    Birkmayer J
    Wien Med Wochenschr; 1988 Jun; 138(11-12):276-8. PubMed ID: 3176507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.
    Silva JM; Silva J; Sanchez A; Garcia JM; Dominguez G; Provencio M; Sanfrutos L; Jareño E; Colas A; España P; Bonilla F
    Clin Cancer Res; 2002 Dec; 8(12):3761-6. PubMed ID: 12473587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. General morphological and biological features of neoplasms: integration of molecular findings.
    Diaz-Cano SJ
    Histopathology; 2008 Jul; 53(1):1-19. PubMed ID: 18282144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.